[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polyglandular-autoimmune-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polyglandular-autoimmune-syndrome":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100494317",false,"NCT05716607","Treatment Study in Patients Treated With Both Insulin & Hydrocortisone","Randomized Cross-over Trial in Patients Treated With Both Insulin & Hydrocortisone","INSCORT","Inclusion Criteria:\n\nMen and women at age 18 to 70 years, with BMI 18-32 kg\u002Fm2 and well-defined both insulin-treated diabetes \\& Addison's disease for \\>12 months each, on insulin treatment and stable hydrocortisone replacement with once-daily dual-release hydrocortisone (20-30 mg\u002Fday) for \\>3 months.\n\nExclusion Criteria:\n\n* Any medication with other glucose lowering agents than insulin\n* Any additional underlying or intercurrent disease that may need regular or periodic pharmacological treatment with glucocorticoids during the study period, including infectious diseases\n* Any medication with agents which in the investigator's judgement might interfere with the study drugs kinetics, including therapies affecting gastrointestinal emptying or motility\n* Any medication with oral estrogen supplementation and\u002For regular DHEA medication for the past 4 weeks\n* Clinically significant renal dysfunction with a serum creatinine above 160 mmol\u002FL\n* Active malignancy\n* Clinical or laboratory signs of significant cerebral, cardiovascular, respiratory, hepatobiliary\u002Fpancreatic disease which in the investigator's judgement may interfere with the study assessment\n* Pregnant or lactating women\n* Alcohol\u002Fdrug abuse or any other condition associated with poor patient compliance, including expected non-cooperation, as judged by the investigator.","ALL","18 Years","70 Years",{"count":20,"type":21},16,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of INS.CORT trial is, by studying glycemic variability in a well-defined patient group with both insulin \\& hydrocortisone (patients with concomitant insulin-treated diabetes \\& Addison's disease) and collecting information about the administration -time point and doses- of insulin, hydrocortisone and food intake with the help of new technology to improve the treatment in all patients treated with both insulin \\& glucocorticoids.",[27,28,29],"Diabetes Mellitus","Adrenal Insufficiency","Polyglandular Autoimmune Syndrome",[31,32,33,34],"Insulin treatment","Hydrocortisone treatment","Opposing effects on glucose metabolism","Randomized Controlled Trial","NOT_YET_RECRUITING","2024-04-28",{"date":38,"type":39},"2024-04-30","ACTUAL",{"date":41,"type":21},"2024-09",{"date":43,"type":21},"2027-12",{"name":45,"class":46},"Vastra Gotaland Region","OTHER_GOV",""]